Clinical Research Directory

Inclusion Criteria: Phases 1 and 2: Interview Inclusion Criteria (per self-report): * Non-US born; * Of Chinese descent; * Age 21 years through 80 years; * Language spoken: Mandarin and/or English * Diagnosis of Stage IV cancer (any type). Phase 3: * Stage III or IV cancer (per self-report or on the MSKCC EMR). If traditional staging does not apply (i.e. for leukemia), we can allow patient deemed by provider to have poor prognosis/roughly equivalent to Stage III or IV to be referred. * Age 18 or older * Of Chinese descent * Mandarin-speaking * Have an estimated life expectancy of at least 6 months (per self-report or on the MSKCC EMR) * Resides in New York State or New Jersey Phase 4: * Stage III or IV cancer (per self-report or on the MSKCC EMR). If traditional staging does not apply (i.e. for leukemia), we can allow patient deemed by provider to have poor prognosis/roughly equivalent to Stage III or IV to be referred. * Age 18 or older * Of Chinese descent * Mandarin-speaking * Have an estimated life expectancy of at least 6 months (per referring physician assessment or on the MSKCC EMR) * Resides in New York State or New Jersey Exclusion Criteria: Phases 1 and 2: * Presence of cognitive impairment disorder (e.g., delirium or dementia) sufficient to preclude meaningful informed consent and/or data collection. The Chinese version of the Mini Mental State Examination (MMSE) (46) will be used as a cognitive screening tool. Patients with MMSE scores below 20 will be excluded. For English speaking patients we will use the English version of the MMSE. * Has a household member who has already participated (or agreed to participate). Phase 3: * Previous participation in Phases 1 or 2 of the study * Unable/unwilling to use or no access to a telehealth platform (i.e., telephone or videoconference) * For participants who express interest in RSMI, unable/unwilling to use Zoom videoconferencing platform * Unable or unwilling to commit to up to 16 weeks to complete 6-session intervention and follow-up assessments * Major psychiatric illness or cognitive impairment that in the judgment of study investigators or study staff would preclude study participation * Patients diagnosed with primary brain tumors (per self-report or on the MSKCC EMR), as they may have difficulty completing the intervention and answering questionnaires * Undergoing hematopoietic stem cell transplantation (HSCT) (per self-report or on the MSKCC EMR) * Currently in psychotherapeutic treatment (patients being treated with psychotropic medications will not be excluded, as long as they are not in psychotherapy; per self report) Phase 4: * Previous participation in Phases 1, 2, or 3 of the study * Unable/unwilling to use or no access to the Zoom videoconferencing platform (required for RSMI) * Unable or unwilling to commit to up to 16 weeks to complete 6-session intervention and follow-up assessments * Major psychiatric illness or cognitive impairment that in the judgment of study investigators or study staff would preclude study participation * Patients diagnosed with primary brain tumors (per self-report or on the MSKCC EMR), as they may have difficulty completing the intervention and answering questionnaires * Undergoing hematopoietic stem cell transplantation (HSCT) (per self-report or on the MSKCC EMR) * Currently in psychotherapeutic treatment (patients being treated with psychotropic medications will not be excluded, as long as they are not in psychotherapy; per self report)